|Drug class||Calcium channel blocker|
|Main uses||High blood pressure, angina|
|Side effects||Swelling, headache, flushing|
|Onset of action||2.5–5 hours|
|Typical dose||2.5 to 10 mg OD|
|Elimination half-life||25 hours|
|Chemical and physical data|
|Molar mass||384.25 g·mol−1|
|3D model (JSmol)|
Felodipine, sold under the brand name Plendil among others, is a medication is used to treat high blood pressure and heart related chest pain (angina). It is one of several first line options. It is taken by mouth.
Common side effects include swelling, headache, and flushing. Other side effects may include syncope and low blood pressure. There are concerns regarding negative effects if used during pregnancy. It is a calcium channel blocker of the dihydropyridine type.
Felodipine was patented in 1978 and approved for medical use in 1988. It is available as a generic medication. In the United Kingdom 4 weeks of 5 mg per day costs about £4 as of 2021. This amount is about 11 USD in the United States. It is also available in combination with ramipril.
Mechanism of action
Different calcium channels are present in vascular tissue and cardiac tissue; an in vitro study on human vascular and cardiac tissues comparing how selective various calcium channel blockers are for vascular compared to cardiac tissue found the following vascular/cardiac tissue ratios: mibefradil 41, felodipine 12; nifedipine 7, amlodipine 5, and verapamil 0.2.: 172
Felodipine is a member of the 1,4-dihydropyridine class of calcium channel blockers.: 20–21 It is a racemic mixture, and is insoluble in water but is soluble in dichloromethane and ethanol.: 25
The Swedish company Hässle, a division of Astra AB, discovered felodipine; it filed a patent application in 1979 claiming felodipine as an antihypertensive drug. Astra partnered this drug and others with Merck & Co. in the US under a 1982 agreement between the companies. The drug was approved by the FDA in 1991 after a three and a half year review; the drug entered a very crowded market the included the other calcium channel blockers nifedipine, verapamil, nicardipine, and isradipine. The FDA gave the drug a 1C rating, meaning that it found little difference between felodipine and the drugs already approved for the same use.
In April 2016, AstraZeneca announced that they were selling the right to market felodipine in China to China Medical System Holdings for $310 million; AZ would continue to manufacture the drug.
Society and culture
As of 2016, felodipine was marketed under many brand names worldwide: Auronal, Cardioplen, Catrazil, Dewei, Dilahex, Enfelo, Erding, Fedil, Fedisyn, Feldil, Felicipin, Felo, Felocard, Felocor, Feloday, Felodil, Felodin, Felodip, Felodipin, Felodipina, Felodipine, Felodipino, Felodistad, Felogard, Felohexal, Felop, Felopine, Felostad, Feloten, Felotens, Felpin, Flodicar, Flodil, Keliping, Keydipin, Lodistad, Modip, Munobal, Nirmadil, Parmid, Penedil, Perfudal, Phelop, Phenodical, Plendil, Plentopine, Polo, Presid, Preslow, Prevex, Renedil, Sistar, Splendil, Stapin, Topidil, Vascalpha, Versant, and XiaoDing.
- "Felodipine Monograph for Professionals". Drugs.com. Archived from the original on 15 August 2020. Retrieved 10 December 2021.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 174. ISBN 978-0857114105.
- "Felopidine UK label". UK Electronic Medicines Compendium. 15 September 2015. Archived from the original on 16 August 2019. Retrieved 9 March 2021.
- Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, Volume 115, 2013, pp. 887-890
- "Felodipine (Plendil) Use During Pregnancy". Drugs.com. Archived from the original on 29 November 2020. Retrieved 10 December 2021.
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 465. ISBN 9783527607495. Archived from the original on 27 August 2021. Retrieved 9 March 2021.
- "Felodipine ER Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 10 December 2021.
- "Felodipine US label" (PDF). FDA. October 2012. Archived (PDF) from the original on 31 March 2021. Retrieved 9 March 2021.
- Kiani J, Imam SZ (October 2007). "Medicinal importance of grapefruit juice and its interaction with various drugs". Nutrition Journal. 6 (33): 33. doi:10.1186/1475-2891-6-33. PMC 2147024. PMID 17971226..
- Luther JM (September 2014). "Is there a new dawn for selective mineralocorticoid receptor antagonism?". Current Opinion in Nephrology and Hypertension. 23 (5): 456–61. doi:10.1097/MNH.0000000000000051. PMC 4248353. PMID 24992570.
- Joshi GS, Burnett JC, Abraham DJ (2003). "Cardiac Drugs: Antianginal, Vasodilators, Antiarrhythmic". In Abraham DJ (ed.). Burger's medicinal chemistry and drug discovery. Volume 3: Cardiovascular Agents and Endocrines (6th ed.). Hoboken, N.J.: Wiley. ISBN 9780471270904.
- "Merck's Plendil (Felodipine) Approved with "1C" Rating". Pink Sheet. 5 August 1991. Archived from the original on 15 November 2016. Retrieved 9 March 2021.
- Astrazeneca AB v. Mutual Pharmaceutical Co. (United States Court of Appeals for the Federal Circuit 2004).Text
- US patent 4,264,611, Berntsson, Peder; Carlsson, Stig & Gaarder, Jan et al., "2,6-Dimethyl-4-2,3-Disubstituted Phenyl-1,4-Dihydro-Pyridine-3,5 Dicarboxylic Acid-3,5-Asymmetric Diesters having Hypotensive Properties, as well as Method for Treating Hypertensive Conditions and Pharmaceutical Preparations Containing Same", issued 28 April 1981, assigned to Aktiebolaget Hassle
- George J (28 July 1997). "Secret of Astra Merck". Philadelphia Business Journal. Philadelphia. Archived from the original on 10 November 2016. Retrieved 7 November 2016.
- "Astra, Merck restructure". CNNMoney. 19 June 1998. Archived from the original on 16 August 2019. Retrieved 7 November 2016.
- Jönsson B (2008). "Sweden". In Rapoport J, Jacobs P, Jonsson E (eds.). Cost Containment and Efficiency in National Health Systems a Global Comparison. Weinheim: Wiley-VCH. p. 218. ISBN 9783527622955. Archived from the original on 21 March 2017. Retrieved 9 March 2021.
- Approved Drug Products with Therapeutic Equivalence Evaluations (PDF) (36th ed.). FDA. 2014. Archived (PDF) from the original on 15 November 2016. Retrieved 9 March 2021.
- "AstraZeneca enters licensing agreement with China Medical System Holdings for hypertension medicine" (Press release). AstraZeneca. 29 February 2016. Archived from the original on 3 March 2021. Retrieved 7 November 2016.
- "International brand names: Felodipine". Drugs.com. Archived from the original on 15 November 2016. Retrieved 15 November 2016.